Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging?

Department of Neurology, University of Virginia Health System, McKim Hall, 1 Hospital Drive, P.O. Box 800394, Charlottesville, VA 22908, United States.
Neurobiology of aging (Impact Factor: 4.85). 11/2007; 28(10):1465-80. DOI: 10.1016/j.neurobiolaging.2006.06.021
Source: PubMed

ABSTRACT For 70 years after Alois Alzheimer described a disorder of tangle-and-plaque dementia, Alzheimer's disease was a condition of the relatively young. Definitions of Alzheimer's disease (AD) have, however, changed over the past 30 years and under the revised view AD has truly become an age-related disease. Most now diagnosed with AD are elderly and would not have been diagnosed with AD as originally conceived. Accordingly, younger patients that qualify for a diagnosis of AD under both original and current Alzheimer's disease constructs now represent an exceptionally small percentage of the diagnosed population. The question of whether pathogenesis of the "early" and "late" onset cases is similar enough to qualify as a single disease was previously raised although not conclusively settled. Interestingly, debate on this issue has not kept pace with advancing knowledge about the molecular, biochemical and clinical underpinnings of tangle-and-plaque dementias. Since the question of whether both forms of AD share a common pathogenesis could profoundly impact diagnostic and treatment development efforts, it seems worthwhile to revisit this debate.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is characterized neuropathologically by synaptic disruption, neuronal loss and deposition of amyloid beta (Aβ) protein in brain structures that are critical for memory and cognition. There is increasing appreciation, however, that astrocytes, which are the major non-neuronal glial cells, may play an important role in AD pathogenesis. Unlike neurons, astrocytes are resistant to Aβ cytotoxicity, which may in part be related to their greater reliance on glycolytic metabolism. Herein we show that in cultures of human fetal astrocytes, pharmacological inhibition or molecular down-regulation of a main enzymatic regulator of glycolysis, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase (PFKFB3), results in increased accumulation of Aβ within and around astrocytes and greater vulnerability of these cells to Aβ toxicity. We further investigated age-dependent changes in PFKFB3 and astrocytes in AD transgenic mice (TgCRND8) that over-express human Aβ. Using a combination of Western blotting and immunohistochemistry, we identified an increase in glial fibrillary acidic protein (GFAP) expression in astrocytes that paralleled escalation of Aβ plaque burden in TgCRND8 mice in an age-dependent manner. Furthermore, PFKFB3 expression also demonstrated an increase in these mice, albeit at a later age (9 months) than GFAP and Aβ. Immunohistochemical staining showed significant reactive astrogliosis surrounding Aβ plaques with increased PFKFB3 activity in 12-month old TgCRND8 mice, when AD pathology and behavioural deficits are fully manifest. These studies shed important light on the unique bioenergetic mechanisms within astrocytes that may contribute to the development of AD pathology. Copyright © 2015, The American Society for Biochemistry and Molecular Biology.
    Journal of Biological Chemistry 03/2015; DOI:10.1074/jbc.M114.618157 · 4.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sporadic Alzheimers disease (sAD) has not been explained by any current theories, so new hypotheses are urgently needed. We proposed that energy and Ca2+ signaling deficits are perhaps the earliest modifiable defects in brain aging underlying memory decline and tau deposits (by means of inactivating Ca2+-dependent protease calpain). Consistent with this hypothesis, we now notice that at least eight other known calpain substrates have also been reported to accumulate in aging and AD. Thus, protein accumulation or aggregation is not a pathogenic event, but occurs naturally and selectively to a peculiar family of proteins, and is best explained by calpain inactivation. Why are only calpain substrates accumulated and how can they stay for decades in the brain without being attacked by many other non-specific proteases there? We believe that these long-lasting puzzles can be explained by calpains unique properties, especially its unusual specificity and exclusivity in substrate recognition, which can protect the substrates from other proteases attacks after calpain inactivation. Interestingly, our model, in essence, may also explain tau phosphorylation and the formation of amyloid plaques. Our studies suggest that a-secretase is an energy-/Ca2+-dual dependent protease and is also the primary determinant for A beta levels. Therefore, beta- and gamma-secretases can only play secondary roles and, by biological laws, they are unlikely to be positively identified. This study thus raises serious questions for policymakers and researchers and these questions may help explain why sAD can remain an enigma today.
    Frontiers in Aging Neuroscience 12/2014; 6. DOI:10.3389/fnagi.2014.00329 · 2.84 Impact Factor
  • Source